HOUSE_OVERSIGHT_024898.jpg
2.14 MB
Extraction Summary
1
People
17
Organizations
5
Locations
3
Events
3
Relationships
3
Quotes
Document Information
Type:
Financial research report / market analysis
File Size:
2.14 MB
Summary
This document is page 82 of a Cowen Collaborative Insights report dated February 25, 2019, analyzing the cannabis and hemp markets in Italy and Switzerland. It details regulatory environments, specifically the 'cannabis light' market in Italy and medical/tobacco substitute regulations in Switzerland, while listing various corporate investments and acquisitions (Wayland, Canopy, CROP). The document bears a 'HOUSE_OVERSIGHT_024898' Bates stamp, indicating it was part of a document production to the House Oversight Committee, likely included in a larger batch of financial records.
People (1)
| Name | Role | Context |
|---|---|---|
| Michael Cella | Recipient |
Email address listed in the sidebar watermark: michael.cella@cowen.com
|
Organizations (17)
Timeline (3 events)
2016
Italy market opened up when government announced hemp cultivation license no longer required.
Italy
2018-06
Changes in Swiss law regarding pharmaceutical grade pure CBD following US FDA approval of Epidiolex.
Switzerland
FDA
Swiss Government
Locations (5)
| Location | Context |
|---|---|
Relationships (3)
Wayland entered a JV with CBD Italian Factory S.S.
LGC Capital entered an agreement with EasyJoint to acquire 47% of the company
Key Quotes (3)
"Italy has a rich history of hemp cultivation and it used to be one of the main producers in the world prior to prohibition of the plant."Source
HOUSE_OVERSIGHT_024898.jpg
Quote #1
"Whereas the rest of the EU requires THC content to be below 0.2%, Italy permits a margin of up to 0.6%."Source
HOUSE_OVERSIGHT_024898.jpg
Quote #2
"These products are predominantly consumed by affluent businesspeople during breaks at work or the end of the day."Source
HOUSE_OVERSIGHT_024898.jpg
Quote #3
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document